Dasolampanel

Dasolampanel

Systematic (IUPAC) name
(3S,4aS,6S,8aR)-6-(3-Chloro-2-(1H-tetrazol-5-yl)phenoxy)decahydroisoquinoline-3-carboxylic acid
Identifiers
CAS Number	503294-13-1
ATC code	None
PubChem	CID 51049972
ChemSpider	25948207
UNII	1P85D6BE9K
Chemical data
Formula	C17H20ClN5O3
Molar mass	377.825 g/mol
SMILES c1cc(c(c(c1)Cl)c2[nH]nnn2)O[C@H]3CC[C@H]4CN[C@@H](C[C@H]4C3)C(=O)O
InChI InChI=1S/C17H20ClN5O3/c18-12-2-1-3-14(15(12)16-20-22-23-21-16)26-11-5-4-9-8-19-13(17(24)25)7-10(9)6-11/h1-3,9-11,13,19H,4-8H2,(H,24,25)(H,20,21,22,23)/t9-,10+,11-,13-/m0/s1 Key:LAKQPSQCICNZII-NOHGZBONSA-N

Dasolampanel (INN, USAN, code name NGX-426) is an orally bioavailable analog of tezampanel and thereby competitive antagonist of the AMPA and kainate receptors which was under development by Raptor Pharmaceuticals/Torrey Pines Therapeutics for the treatment of chronic pain conditions including neuropathic pain and migraine.^[1] It was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered by intravenous injection,^[2][3] but ultimately neither drug was ever marketed.

See also

• Irampanel
• Selurampanel

References

1. Ian P. Stolerman (31 July 2010). Encyclopedia of Psychopharmacology. Springer Science & Business Media. pp. 514–. ISBN 978-3-540-68698-9.
2. Jes Olesen; Nabih Ramadan (21 August 2008). Innovative Drug Development for Headache Disorders. Oxford University Press. pp. 188–. ISBN 978-0-19-955276-4.
3. Gary S. Firestein; Ralph Budd; Sherine E Gabriel; James R O'Dell; Iain B. McInnes (31 August 2012). Kelley's Textbook of Rheumatology: Expert Consult Premium Edition: Enhanced Online Features. Elsevier Health Sciences. pp. 1031–. ISBN 1-4557-3767-4.